History & Overview Annual Report President's Pages Center News Community Affairs
Make a Gift Yankees Universe Fund Fred's Team Thomas Blake Sr. Memorial Research Fund Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck Cookbook
Press Releases Information for Journalists News@MSKCC
Manhattan New Jersey Long Island Westchester
Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days Job Search & Apply Online
Making an Appointment
Bladder Cancer Nomogram
Bladder Cancer Nomogram
This prediction tool calculates the risk of recurrence of bladder cancer five years after radical cystectomy

The most common type of bladder cancer is transitional cell carcinoma, also known as urothelial carcinoma, which can be either noninvasive (confined to the bladder surface) or invasive (in the bladder muscle or in areas beyond the bladder). Transitional cell carcinoma sometimes occurs in other parts of the urinary system including the renal pelvis, ureters, and urethra. Less common types of bladder cancers include squamous cell carcinoma, adenocarcinoma, and small cell carcinoma.   

According to the American Cancer Society, about 67,160 Americans will be diagnosed with bladder cancer in 2007. New therapies for bladder cancer and improved diagnostic tools have led to a steady decline in deaths from the disease since the early 1970s.

In this section, you can find information about our expertise in treating patients with bladder cancer, the services we offer patients with this condition, and research under way at Memorial Sloan-Kettering.

  • Our Approach & Expertise
    Memorial Sloan-Kettering doctors treat nearly 400 bladder cancer patients each year. Our goal is to provide comprehensive therapy, delivered with the highest quality of care, to optimize each patient's chance of cure.
  • Our Team of Experts
    Our team of doctors includes urologists, medical oncologists, radiation oncologists, pathologists, radiologists, and specialty nurses who work together to diagnose and treat patients with bladder cancer.
  • Overview
    Approximately 67,160 Americans will be diagnosed with bladder cancer in 2007. The most common type of bladder cancer -- transitional cell carcinoma (TCC), also known as urothelial carcinoma -- accounts for about 90 percent of cases.
  • Risk Factors
    The most significant risk factor for bladder cancer is cigarette smoking. A smoker's risk of developing the disease is twice that of a nonsmoker. Occupational exposures to various chemicals may also increase the risk of bladder cancer.
  • Symptoms
    The most common symptom of bladder cancer is blood in the urine, which is not always visible to the naked eye and is usually not accompanied by pain.
  • Diagnosis
    Physicians usually diagnose bladder cancer by examining cells in the urine under a microscope and by inspecting the bladder with a cystoscope.
  • Treatment
    The treatment for bladder cancer depends on the stage of disease at the time of diagnosis.
  • Our Clinical Trials
    A continually updated listing of Memorial Sloan-Kettering's current clinical trials for bladder cancer.
  • Survivorship & Support
    Ensuring a high quality of life for patients with bladder cancer begins with the first stages of treatment and continues with a routine of follow-up exams and tests even after treatment is completed.

PrintEmail This Page